Market uptake of new antiviral drugs for the treatment of hepatitis C
- 29 May 2008
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 49 (4) , 528-536
- https://doi.org/10.1016/j.jhep.2008.04.021
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- Current therapy for hepatitis CInternational Journal of Colorectal Disease, 2005
- Update on Chronic Hepatitis CClinical Gastroenterology and Hepatology, 2005
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis CGut, 2003
- National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10-12, 2002Hepatology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trialsBMJ, 2001
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- EASL International Consensus Conference on Hepatitis CParis, 26–27 February 1999Consensus StatementJournal of Hepatology, 1999